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Respect for fundamental rights, protection of public health, well-being, social cohesion 
and security are the objectives that guide the actions taken by the European Union in the 
fi eld of illicit drugs. The EU drugs strategy 2005–12 provides the framework for enhanced 
coordination between action taken at national, EU and international level and commits the 
members of the EU to tackle illicit drugs by striking a balance between reducing supply 
and demand. 
This publication brings together some of the key frequently asked questions on the EU’s 
drugs policy and how it functions. Further details can be found via the websites and 
other links provided at the end of each answer.
1.  What are the competences of the EU in the fi eld of drugs under 
the Lisbon Treaty?
The Treaty of Lisbon, which entered into force on 1 December 2009, provides the 
Union with simplifi ed working methods and voting rules, streamlined and modernised 
institutions, fi t for an EU of 27 Member States. Two articles explicitly mention drugs: 
Article 83 TFEU and Article 168 TFEU. Pursuant to Article 83, the EU can approximate 
the defi nition of drug traffi cking offences and the related sanctions thereof. According 
to Article 168, the EU shall complement the Member States’ action in reducing drugs-
related health harms, including action on information and prevention, and encourage 
cooperation between them. The Commission, in close contact with the Member States, 
may take initiatives aimed at establishing guidelines and indicators, organise exchange 
of best practice and prepare periodic monitoring and evaluation. 
The Treaty of Lisbon also covers illicit drugs indirectly in other policy fi elds, for example 
trade or internal market. 
The text of the Treaty of Lisbon is available at: http://eur-lex.europa.eu/en/index.htm
2. Who are the main actors of EU drugs policy? 
Key players at EU level are the Council of the European Union (Member States), the 
European Commission and the European Parliament. EU agencies such as the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol play a 
crucial role, as do the European Centre for Disease Prevention and Control (ECDC), the 
European Medicines Agency (EMA) and Eurojust. 
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3.  What are the main features of the ‘European approach on drugs’? 
The EU has, since the 1990s, developed a ‘European approach on drugs’ which 
is refl ected in the EU drugs strategies and drug action plans. This approach is 
comprehensive and multidisciplinary, focusing simultaneously on two pillars: drug-
demand reduction and drug-supply reduction, as well as on three cross-cutting themes: 
international cooperation, coordination and information, and evaluation and research. 
For more information, see:
http://register.consilium.europa.eu/pdf/en/04/st15/st15074.en04.pdf
4. What is meant by drug-demand reduction?
Drug-demand reduction covers a broad range of measures to address substance use. 
It includes prevention measures for the general public or for specifi c target groups. It 
also implies drug treatment for those who have developed drug dependence. Harm 
reduction includes specifi c measures to prevent and reduce the spread of blood-
borne infectious diseases and avoid drug-related deaths, but also aims to increase 
the number of drug users that receive health and social care. Rehabilitation and 
reintegration are aimed at bringing (dependent) drug users back into society, in 
particular those who have been socially marginalised and excluded.
5. What is meant by drug-supply reduction?
The EU action on drug-supply reduction aims at preventing and reducing drug-
related crimes, including production and traffi cking of drugs. EU Member States’ law 
enforcement agencies cooperate in the fi ght against drug production and traffi cking by 
carrying out joint investigations or customs operations. At EU level, policies on anti-
money laundering and confi scation of assets also help combat drug-related crime. In 
recent years, Member States and the Commission have increasingly worked together 
to disrupt drug traffi cking along major supply routes to Europe, in particular from Latin 
America via West Africa and from Afghanistan via Central Asia, Russia and the Western 
Balkans.
6. Why are the EU drugs action plans important? 
The EU drugs action plans are the instruments through which the EU drugs strategy 
is implemented. They contain specifi c objectives, actions and indicators covering 
all relevant policy areas. The action plan serves as a coordinating tool providing 
the framework for cooperation or joint action on illicit drugs in the EU. Despite the 
differences in approaches to illicit drugs, cultural traditions and policy responses, drug 
policies in the EU Member States are increasingly converging, while still respecting the 
principle of ‘Unity in diversity’. 
For more information, see:
http://ec.europa.eu/justice/policies/drugs/policies_drugs_intro_en.htm
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7. Are the EU action plans evaluated? How?
The EU action plans on drugs are evaluated. In 2008, the Commission evaluated the EU 
drugs action plan 2005–08 — the fi rst action plan implementing the EU drugs strategy 
for 2005–12. By 2012, the EU drugs strategy and the EU drugs action plan 2009–12 
will also be subject to an independent evaluation.
The Commission also publishes an annual assessment of the implementation of the action 
plan. This involves gathering information on progress to date from the EU Member 
States, the EMCDDA and Europol. To assess the impact of the EU’s policy on drugs in the 
Member States, the evaluations also include surveys that take into account developments 
at national level.
For more information, see: 
http://ec.europa.eu/justice/policies/drugs/policies_drugs_intro_en.htm
8. How does the EU deal with precursors? 
Drug producers need chemicals called ‘precursors’ to manufacture illicit drugs such as 
heroin, cocaine, ecstasy or amphetamines. There is no production of many illicit drugs 
without drug precursors. Many of these drug precursors have wide legitimate uses (e.g. 
in the synthesis of plastics, pharmaceuticals, cosmetics, perfumes, detergents or aromas), 
but can be diverted from the licit distribution channels.
The EU and all EU Member States are Contracting Parties to Article 12 of the UN 1988 
Convention. Legislation on the prevention of diversion of drug precursors from the trade 
between the EU and third countries as well as intra-EU trade is adopted at EU level and 
is directly applicable in the EU Member States. By enforcing the EU drug precursor 
legislation (1), the EU strives to prevent the diversion of drug precursors through the 
control and monitoring of their legitimate trade. This involves not only close cooperation 
between the competent national authorities (notably health, police and customs 
agencies) but also close cooperation with the private sector and third countries. 
Some important drug precursors are produced in third countries. Therefore, the EU 
is increasingly entering into agreements with the countries concerned to help prevent 
the diversion of drug precursors. Finally, the EU cooperates actively with UN bodies 
dealing with drug precursors, including the United Nations Offi ce on Drugs and Crime 
(UNODC) and the International Narcotics Control Board (INCB).
For more information, see: 
http://ec.europa.eu/taxation_customs/customs/customs_controls/drugs_precursors/
index_en.htm
(1)  Council Regulation (EC) No 111/2005; Regulation (EC) No 273/2004; Commission 
Regulation (EC) No 1277/2005.
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9.  How does the EU act at international level on drugs issues? 
The EU cooperates with and supports the international organisations working in the 
fi eld of drugs. Moreover, cooperation in the fi eld of drugs, based on the principle of 
shared responsibility, proportionality and with full respect for human dignity and human 
rights, is an integral part of agreements with countries and regions throughout the world. 
The EU provides support to and coordinates with third countries on demand reduction, 
supply reduction, alternative development for drug producers, information and capacity 
building against drug traffi cking. This assistance covers EU candidate and potential 
candidate countries, as well as countries that are part of the stabilisation and association 
process (such as Croatia, Turkey and the countries of the Western Balkans region). It also 
helps the countries that are part of the European Neighbourhood Policy (2) and Russia 
to cooperate more closely on drugs through technical assistance programmes such as 
TAIEX. In addition, the EU has developed and fi nanced a range of drugs-related projects 
in Latin America, the Caribbean and West Africa, to improve cooperation along the 
cocaine traffi cking route, and in Afghanistan and Central Asia along the heroin route. 
At international level, the EU works closely together with and is a major donor for 
international partners such as UNODC, INCB, UNAIDS, the World Health Organization 
(WHO), the Council of Europe and the World Customs Organization (WCO). Finally, the 
EU participates actively in the work of the United Nations Commission on Narcotic Drugs in 
Vienna, where the EU Member States work together to act as a coherent group of nations. 
10.  What assistance does the EU provide for candidate and 
potential candidate countries? 
The EU provides technical assistance to help candidate and potential candidate 
countries (3) to develop the structures, strategies, human resources and management skills 
needed to strengthen their economic, social, regulatory and administrative capacity. 
 The Instrument for Pre-accession Assistance (IPA) provides funding for all pre-
accession activities covering:  transition assistance and institution building; cross-
border cooperation; regional development; human resources development; and rural 
development. In the fi eld of drugs, IPA supports the technical cooperation between the 
EMCDDA and Turkey, Croatia and the Western Balkans. 
The Technical Assistance and Information Exchange Instrument (TAIEX) provides short-
term technical assistance in the form of seminars, expert and study visits, training etc. 
For more information, see: http://ec.europa.eu/enlargement/how-does-it-work/technical-
assistance/index_en.htm and http://ec.europa.eu/enlargement/taiex/index_en.htm
(2)  European Neighourhood Policy countries are: Algeria, Armenia, Azerbaijan, Belarus, Egypt, 
Georgia, Israel, Jordan, Lebanon, Libya, Moldova, Morocco, Occupied Palestine Territories, 
Syria, Tunisia and Ukraine.
(3)  Candidate countries are: Croatia, Former Yugoslav Republic of Macedonia, Iceland and 
Turkey; potential candidate countries are: Albania, Bosnia-Herzegovina, Kosovo under UN 
Security Council Resolution 1244, Montenegro and Serbia.
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11.  What assistance does the EU provide for the European 
Neighbourhood Policy (ENP) partners? 
The ENP action plans place drugs cooperation within the framework of the fi ght against 
organised crime and regional cooperation as well as national efforts to develop adequate 
prevention, treatment and rehabilitation programmes. The TAIEX instrument is at the 
disposal of ENP countries and Russia to help build capacity to formulate strategies. 
The European Neighbourhood Policy and Partnership Instrument (ENPI) provides 
funding to support reforms in the ENP countries and funds are allocated according to 
the priorities and needs agreed together with the benefi ciary countries in the individual 
country programmes. 
The Commission encourages the ENP partners to use the ENPI to implement the drugs 
priorities under the ENP action plans. Cooperation between the ENP countries and the 
EU agencies, such as the EMCDDA, is encouraged. 
For more information, see: http://ec.europa.eu/world/enp/faq_en.htm
12. What does the EU do regarding new drugs?
In the EU, new psychoactive substances — mostly synthetic — emerge on a regular basis 
in the drugs market, in particular in the recreational and clubbing circuit. These new, 
unknown and untested substances may pose health risks for consumers. Council Decision 
2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and 
control of new psychoactive substances enables the EU institutions and Member States 
to evaluate the risk of new and potentially threatening narcotic and psychotropic drugs 
(natural and synthetic alike) that appear on the European drug scene. It also enhances 
their capacity to detect and monitor new trends in drug use. A new psychoactive substance 
is defi ned as a new narcotic or psychotropic drug, in pure form or in preparation, that is 
not controlled by the 1961 United Nations Single Convention on Narcotic Drugs or the 
1971 United Nations Convention on Psychotropic Substances, but which may pose a 
public health threat. The decision relates to end-products and not to chemical precursors 
used in the illicit manufacture of narcotic drugs and psychoactive substances.
Between 1997 and 2009, ten psychoactive substances underwent risk-assessment 
procedures. Of these, six phenethylamines (4-MTA, PMMA, 2C-I, 2C-T-2, 2C-T-7 and 
TMA-2) and one piperazine (BZP) were subsequently controlled at EU level. 
For more information, see: 
http://www.emcdda.europa.eu/drug-situation/new-drugs
13. What is the Early warning system? 
When a new psychoactive substance is fi rst detected, detailed information on the 
manufacture, traffi c and use, including information on possible medical use is sent by 
the EU Member States to Europol in the Hague and to the EMCDDA in Lisbon via the 
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Europol National Units and the Reitox national focal points on drugs. Europol and 
the EMCDDA collect the information and communicate it immediately to the Europol 
National Units and the Member States’ representatives in the Reitox network, the 
European Commission and the London-based European Medicines Agency (EMA).
If Europol and the EMCDDA consider that the information provided by the Member 
States on a new psychoactive substance merits further data collection and analysis, they 
submit a Joint Report to the Council, the EMA and the Commission. Based on the Joint 
Report, the Council may request a risk assessment of the health and social risks caused 
by the use and the manufacture of — and traffi c in — a new psychoactive substance, 
the involvement of organised crime and possible consequences of control measures. On 
the basis of the risk assessment report, the Commission decides whether to propose to 
the Council to make a new psychoactive substance subject to drug-control measures. 
For more information, see: http://www.emcdda.europa.eu/drug-situation/new-drugs
14.  Where can I fi nd information on national and EU drug legislation? 
The European Legal Database on Drugs (ELDD) is the EMCDDA’s online database of 
information on drugs-related legislation for the Member States and Norway and for 
the European Union. Information for non-EU countries is being added as it becomes 
available. The database contains legal texts in original formats to allow researchers 
and analysts to consult data sources directly — an indispensable tool for monitoring 
and analysing legislative developments in the Member States. It also contains country 
profi les, presenting the situation in the EU Member States, which have been compiled 
from reports submitted by the Reitox national focal points and from the texts of national 
laws and regulations. Legal reports, including detailed reports and publications on 
various aspects relevant to the legal situation in the EU Member States, are also 
available. Under ‘topic overviews’, summary tables give a quick outline of the legal 
position of EU countries with regard to illicit drugs. 




15. What about civil society? 
Civil society plays an important role in addressing drug issues at local, national and 
international level. In order to develop balanced and effective drug policies, the EU 
needs to tap into the wealth and diversity of experience, knowledge and views of 
groups and associations supporting or representing drug users or their families, NGOs 
directly engaged in reaching out to drug users and other players who have valuable 
insight.
The Civil Society Forum on Drugs meets at least once a year and serves as a platform 
for informal exchanges of views and information between the Commission and civil 
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society organisations. The overall objective of the forum is to feed specifi c grass-roots 
experience into future Commission initiatives on drugs.
For more information, see: 
http://ec.europa.eu/justice/policies/drugs/forum/policies_drugs_forum_en.htm
In order to provide a platform and networking opportunities for civil society bodies in the 
EU Member States, the European Commission launched the European Action on Drugs 
(EAD) on 26 June 2009 (UN World Drugs Day).
At the heart of the EAD campaign are the voluntary commitments made by professionals, 
individuals, associations and institutions to raise drugs awareness at local level.
The EAD fulfi ls one of the objectives of the EU action plan on drugs (2009–12), which 
aims to make EU drug policies relevant to professionals and civil society, while enabling 
them to infl uence policy. 
For more information, see: www.action-drugs.eu 
16. What is Reitox and what is a national drugs observatory?
The EMCDDA relies on a network of national focal points or national drugs 
observatories — the Reitox network — which is responsible for collecting data at 
national level. Today, the Reitox network delivers a consistent, harmonised and 
standardised national reporting package covering 30 countries each year.
A national drugs observatory (NDO) is an organisation that provides its country with 
factual, objective, reliable and comparable information concerning drugs and drug 
addiction and their consequences.
The objectives of the NDO are:
• to provide its national audience with the information seen as essential for 
policymaking and for the organisation of drug-related services, and on drug-related 
issues of general interest; 
• to collect and to produce the information needed to fulfi l its country’s reporting 
obligations to supranational and international monitoring and drug-control 
programmes.
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This information brochure is a joint publication between the 
EMCDDA and the European Commission. It provides answers to the 
most commonly asked questions on EU drug policy collated by the 
Commission and the agency over several years. It aims to provide 
a quick guide to countries outside the EU on key actors, legislation, 
mechanisms and international cooperation in this area. The brochure 
exists in English and French language versions. 
About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) is the hub of drug-related information in Europe. Its mission 
is to provide the EU and its Member States with ‘factual, objective, 
reliable and comparable information’ on drugs, drug addiction 
and their consequences. Established in 1993, it opened its doors in 
Lisbon in 1995 and is one of the EU’s decentralised agencies. With 
a 100-strong multidisciplinary team, the agency offers policymakers 
the evidence base they need for drawing up drug laws and strategies. 
It also helps professionals and researchers pinpoint best practice 
and new areas for analysis. As well as gathering information on the 
demand and reduction of the demand for drugs, the agency in recent 
years has extended its monitoring and reporting on drug supply, 
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